You are now viewing a subsequent follow-up analysis of the MajesTEC-1 trial. This information is not included in the current full Prescribing Information.
At the time of the follow-up report, 25/110 (22.7%) of subjects were still on treatment.2
Response rates with 30‡ months of
median follow-up
Response rates with 30 months
for median follow-up1,2*
46.4% of patients
experienced ≥CR‡
with TECVAYLI® in the MajesTEC-1 trial1
Patients achieved ≥CR‡ at a median time of
6.0
months2 (range: 1.7-18.5 months)
Depth of response
46.4% ≥CR† was demonstrated in the MajesTEC-1 trial
Duration of response
21.6 months mDOR(95% CI,14.9-NE)
*Based on a median duration of follow-up of 29.9 months.2
†ORR: sCR+CR+VGPR+PR.
‡≥CR: sCR+CR.
§≥VGPR: sCR+CR+VGPR.
CI, confidence interval; CR, complete response; mDOR, median duration of response; ORR, overall response rate; PR, partial response; sCR, stringent complete response; VGPR, very good partial response.
References:
- Garfall AL, Nooka AK, Niels WCJ van de Donk, et al. Long-term follow-up from the phase 1/2 MajesTEC-1 trial of teclistamab in patients with relapsed/refractory multiple myeloma. Poster. Presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting; May 31-June 4, 2024; Chicago, IL.
- Data on file. Janssen Biotech, Inc.
